



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/800,031

03/15/2004

Tara Lynn Bielski

21196/0212443-US0

6868

7278

7590

03/24/2010

DARBY & DARBY P.C.

P.O. BOX 770

Church Street Station

New York, NY 10008-0770

EXAMINER

BARHAM, BETHANY P

ART UNIT

PAPER NUMBER

1615

MAIL DATE

DELIVERY MODE

03/24/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/800,031	Applicant(s) BIELSKI ET AL.	
	Examiner BETHANY BARHAM	Art Unit 1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 January 2010.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-66 is/are pending in the application.
- 4a) Of the above claim(s) 61-65 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-60 and 66 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Summary

Receipt of Applicant's Response filed on 01/15/10 is acknowledged. Claims 1-66 are pending, 61-65 remain withdrawn. Claims 1-60 and 66 are rejected.

MAINTAINED REJECTIONS

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-60 and 66 is rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,772,473 ('473) in view of US 2003/0180359 ('359) or US 4,792,452 ('452) and US 5,415,871 ('871).

The instant claims are drawn to an orally administrable formulation for administering nitrofurantoin to a patient in need thereof which comprises: a first component being a controlled release form and a second component being an immediate release form, wherein (a) said first component comprises nitrofurantoin monohydrate, sodium alginate, alginic acid and hypromellose; (b) said second component comprises macrocrystalline nitrofurantoin; and (c) said formulation provides

Art Unit: 1615

a therapeutically effective combination of said nitrofurantoin monohydrate and said macrocrystalline nitrofurantoin.

- '473 teaches all the limitations of the instant claims except the first component controlled release excipients. '473 teaches a combination sustained/rapid release pharmaceutical capsule for oral administration of nitrofurantoin comprising a first particulate of nitrofurantoin and sustained release excipients (ie PVP and carboxyvinyl polymer) and a second particulate comprising macrocrystalline nitrofurantoin (abstract, col.5, lines 35-39 and col. 8, lines 18-27). The first particulate comprising nitrofurantoin is nitrofurantoin monohydrate (examples, col. 10, lines 45 and 57-67) (according to the limitations of claim 1).
- '473 teaches that the components are "particulate mixtures" such as powders, granules, etc (col. 3, lines 46-47) and that in the sustained release mixture (first particulate) are uniformly mixed (col. 6, lines 22-26) and that the components can be layered or enclosed in smaller units within the capsule shell containing the entire dosage form (abstract, col. 4, lines 1-19) (meeting the limitations of claims 2, 4-10, 41, 43-52, and 54-60).
- '473 teaches first particulate comprising nitrofurantoin is nitrofurantoin monohydrate (examples, col. 10, lines 45 and 57-67) in amounts of 150-161.4 mg and also generally 50-1000 mg, preferably 100-400, more preferably 150-250mg per capsule (col.6, lines 18-51) (meeting the limitations of claims 11-13). '473 teaches the second particulate comprising macrocrystalline nitrofurantoin is amounts of 10-200 mg, pregerably 25-100 mg (col. 6, lines 6-8) (meeting the

Art Unit: 1615

limitations of claims 14-16) and thus the ratios of the drugs overlap with those instant claimed in claims 30, 33, 37 and 40).

- '473 teaches the sustained release polymers in amount of 5-86% and 4-40%, etc (col. 7, lines 5-7 and col. 8, lines 29-30) (meeting the limitations of claims 17-26, 30 and 37).
- '473 teaches diluents, fillers, coloring agents, etc (col. 8, lines 48-col. 9, lines 6) and coating the dosage (col. 9, lines 28-39) and about 5% of colorants such as zinc stearate (Examples) (meeting the limitations of claims 28-29, 31-32, 36, 38-39 and 66).
- Stearic acid, talc, lactose, sucrose, etc are all taught as excipients (col. 8, lines 48-col. 9, lines 6) (meeting the limitations of claims 34-35).

'473 does not teach a tablet (instant claims 3, 42, and 53), specific percentages instant claimed, or the sustained release polymers of the first component of alginic acid, sodium alginate and hydroxypropylmethylcellulose (instant claims 1 and 27), but does teach a first particulate comprising nitrofurantoin monohydrate and sustained release polymers/excipients and overlapping percentages.

- '359 teaches multi-layer dosage forms including caplets, tablets, etc [0020] (instant claims 3, 42, and 53). '359 also teaches that controlled release polymers/excipients useful in the active layer include PVP, HPMC (ie hypromellose), carboxyvinylpolymers, alginic acid and derivatives such as sodium alginate [0038]. '359 teaches specifically preferred polymeric substances

Art Unit: 1615

for the active layer include a combination of one or more of a) and b), where a) includes HPMC and b) includes alginic acid, sodium alginate [0041] (meeting the limitations of instant claims 1 and 27).

- '452 teaches a controlled release formulation comprising a pharmaceutical and polymers of alginic acid such as sodium alginate and HPMC (abstract, col. 1, lines 11, col. 3, lines 15-60 and Examples). '452 teaches that mixtures of the same or different alginic acid derivatives can be used (col. 3, lines 28-30) (meeting the limitations of instant claims 1 and 27). While '871 teaches that polymer having sustained release properties include sodium alginate or alginic acid and HPMC (col. 4, lines 13-20) and that the can be formulated into any solid dosage such as a gelatin capsule, tablet, etc (col. 6, lines 29-34) (instant claims 3, 42, and 53).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to combine '473 in view of '359 or '452 and '871. A skilled artisan would know how to substitute the sustained release polymers and/or tablet form of '359 or '452 and '871 for the polymers and/or capsule in the product of '473 with predictable results. Such a substitution of one sustained release polymer for another sustained release polymer is within the purview of the skilled artisan and would yield predictable results.

Furthermore, adjusting the percent of a compound in the formulation is simple optimization and known to a skilled pharmacologist. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454,456, 105 USPQ

Art Unit: 1615

233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 ("The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages."); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969).

Response to Arguments

Applicant's arguments with respect to claims 1-60 and 66 have been considered but are not persuasive. Applicant's argue that "one of ordinary skill in the art would not have replace the sustained release excipient PVP with the instantly claimed excipients or any other excipient, because to do so would omit a "necessary ingredient" to achieve sustained release of nitrofurantoin" (response bottom of page 2- top of page 3) and that "[c]arboxyvinylpolymer is another necessary ingredient..." of '473. The Examiner respectfully disagrees as the prior art '473 teaches that PVP and carboxyvinylpolymer provide 'the desired sustained release function' and as such are disclosed sustained release excipients controlling the release of the drug and according to '359 (for example) PVP, HPMC (ie hypromellose), alginic acid and sodium alginate are all known

Art Unit: 1615

to prove sustained/controlled release [0039]; also carboxyvinylpolymers, alginic acid and sodium alginate are known viscosity-increasing agents and are equivalents [0040]; and that combinations of HPMC (ie hypromellose), alginic acid and sodium alginate are preferred [0039, 0041-0043]. Further the Examiner respectfully points out that '359 or '452 and '871 teach that HPMC, alginic acid and sodium alginate are preferred over the disclosed PVP and carboxyvinylpolymers of '359 and '472 and as such it would be obvious to substitute the preferred excipients of '359 or '452 and '871 into the composition of '473 with predictable results. Applicant has not shown any factual evidence (data, side-by-side comparison) why the excipients are not equivalents or would have unexpected results and cannot be substituted one for another as mere argument by counsel is not persuasive (see MPEP 716.01).

Applicant further argues that '359 or '452 and '871 do not disclose nitrofurantoin. The Examiner respectfully points out that applicant's argue against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

Conclusions

Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1615

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bethany Barham whose telephone number is (571)272-61755. The examiner can normally be reached on M-F, 8:30 am to 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert A. Wax can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Bethany Barham
Art Unit 1615

/S. TRAN/
Primary Examiner, Art Unit 1615